Adv in Oncology Mailer Printout
11/17/04
1:40 PM
Page 8
ADV A N C E S IN Oncology
An Int e rac t ive CME A u dio c onfer e nc e S e ries
Eme r ging S t ra t e gies f o r
Impr o v ing Out c omes in
Multiple Myeloma
Robert Rifkin, MD, FACP
Medical Director
Rocky Mountain Blood and Marrow Transplant Program
US Oncology
Denver, CO
Robert Orlowski, MD, PhD
Assistant Professor of Medicine
Lineberger Comprehensive Cancer Center
University of North Carolina
Chapel Hill, NC
This program is sponsored by Medical Education
This program is supported through an unrestricted
Resources (MER), a non-profit medical education
educational grant from
company in Littleton, Colorado.
MEDICAL
EDUCATION
RESOURCES, INC.
A Non-Profit Organization

---

Adv in Oncology Mailer Printout
11/17/04
1:40 PM
Page 1
Emerging Strategies for Improving Outcomes in
Multiple Myeloma
Program Overview
Multiple myeloma will account for approximately 15,270 new cancer cases in 2004 and result in
an estimated 11,070 deaths. Although multiple myeloma is sensitive to both chemotherapy and
radiation therapy, it remains incurable at present and durable complete responses are rare. The
median survival with standard treatment is approximately 33 months, highlighting the importance
of developing novel treatment approaches for improving outcomes in patients with multiple
myeloma.
Patients with multiple myeloma are generally classified into four categories of prognostic
significance: smoldering myeloma, Durie-Salmon stage I myeloma, plasmacytoma, or more
advanced stages of systemic myeloma. Management of patients varies by stage of disease and
individual patient characteristics; however, concurrent with the management of specific complications,
chemotherapy should be instituted promptly to reduce the number of malignant plasma cells.
Patients with smoldering (indolent) or stage I myeloma should be observed and no initial treatment
is required; however, if their disease progresses to stage II or higher, primary therapy with
conventional chemotherapy and bisphosphonates should be initiated. De novo patients who are
eligible, should be considered for an autologous transplant as randomized trials have shown that
this approach is superior to conventional chemotherapy. Conventional chemotherapy for patients
with advanced multiple myeloma include oral melphalan/dexamethasone (MD) or vincristine/
doxorubicin/dexamethasone (VAD). Thalidomide/dexamethasone (THAL/DEX) is also an option
based on results from several clinical trials. Additionally, recent clinical findings also indicate that
liposomal doxorubicin/vincristine/dexamethasone (DVD) is also a treatment option that provides
similar efficacy to VAD while allowing easier administration and a more favorable toxicity profile.
For patients with progressive disease who received MD as their primary therapy, VAD or DVD are
acceptable treatment options. Additional strategies for salvage therapy include cyclophosphamide-VAD
(C-VAD), etoposide/dexamethasone/cytarabine/cisplatin (EDAP), high-dose cyclophosphamide,
and thalidomide. For patients who have progressed and received at least two prior therapies,
bortezomib should be considered
Ongoing clinical trials continue to evaluate novel treatment strategies in an effort to improve
outcomes in patients with multiple myeloma. Encouraging preliminary results have been reported
for one such strategy, the combination of liposomal doxorubicin/vincristine/reduced-dose
dexamethasone (DVd) and thalidomide, in patients with newly diagnosed myeloma. The treatment
of multiple myeloma is complex and a continuous reexamination of treatment approaches is
necessary to improve outcomes.

---

Adv in Oncology Mailer Printout
11/17/04
1:40 PM
Page 2
Emerging Strategies for Improving Outcomes in
Multiple Myeloma
Learning Objectives
After participating in this program, the participant should be able to:
1. Describe current treatment options for patients with newly diagnosed, primary resistant, and
relapsing multiple myeloma.
2. Review limitations of current treatment options.
3. Explain the prognostic significance of response to therapy and progression-free survival.
4. Discuss emerging data for novel treatment strategies for managing patients with
multiple myeloma.
5. Describe strategies to reduce toxicities and adverse effects associated with treatments.
6. Explain the rationale of current clinical trials designed to improve treatment outcomes.
Target Audience
This activity is designed for physicians, nurses, and pharmacists involved in the clinical care and
treatment of patients with multiple myeloma.
Program Goal
This program will provide a review of the management of multiple myeloma and examine recent clinical
data for emerging treatment strategies and discuss their integration into clinical practice.
Agenda
Primary Treatment Strategies for Multiple Myeloma
Robert Rifkin, MD, FACP
Medical Director
Rocky Mountain Blood and Marrow Transplant Program
US Oncology
Denver, CO
Treatment Strategies for Relapsed/Refractory Multiple Myeloma
Robert Orlowski, MD, PhD
Assistant Professor of Medicine
Lineberger Comprehensive Cancer Center
University of North Carolina
Chapel Hill, NC
Questions & Answers

---

Adv in Oncology Mailer Printout
11/17/04
1:40 PM
Page 3
Emerging Strategies for Improving Outcomes in
Multiple Myeloma
Audioconference Schedule
DATE
DAY
EST
CST
MST
PST
November 17, 2004
Wednesday
6:00 PM
5:00 PM
4:00 PM
3:00 PM
November 18, 2004
Thursday
12:00 PM
11:00 AM
10:00 AM
9:00 AM
November 19, 2004
Friday
2:00 PM
1:00 PM
12:00 PM
11:00 AM
Myeloma
November 22, 2004
Monday
12:00 PM
11:00 AM
10:00 AM
9:00 AM
November 29, 2004
Monday
8:00 PM
7:00 PM
6:00 PM
5:00 PM
December 13, 2004
Monday
8:00 PM
7:00 PM
6:00 PM
5:00 PM
Multiple
in
December 15, 2004
Wednesday
12:00 PM
11:00 AM
10:00 AM
9:00 AM
December 16, 2004
Thursday
1:00 PM
12:00 PM
11:00 AM
10:00 AM
TE(S)A
December 17, 2004
Friday
2:00 PM
1:00 PM
12:00 PM
11:00 AM
D
Outcomes
December 22, 2004
Wednesday
3:00 PM
2:00 PM
1:00 PM
12:00 PM
January 17, 2005
Monday
7:00 PM
6:00 PM
5:00 PM
4:00 PM
CHECK
oving
January 19, 2005
Wednesday
1:00 PM
12:00 PM
11:00 AM
10:00 AM
Impr
PLEASE
January 20, 2005
Thursday
6:00 PM
5:00 PM
4:00 PM
3:00 PM
for
January 21, 2005
Friday
1:00 PM
12:00 PM
11:00 AM
10:00 AM
January 24, 2005
Monday
12:00 PM
11:00 AM
10:00 AM
9:00 AM
ategies
January 26, 2005
Wednesday
3:00 PM
2:00 PM
1:00 PM
12:00 PM
Str
January 27, 2005
Thursday
6:00 PM
5:00 PM
4:00 PM
3:00 PM
ging
January 28, 2005
Friday
3:00 PM
2:00 PM
1:00 PM
12:00 PM
Emer
February 23, 2005
Wednesday
3:00 PM
2:00 PM
1:00 PM
12:00 PM
February 24, 2005
Thursday
6:00 PM
5:00 PM
4:00 PM
3:00 PM
How to Register
There is no fee for participation in this activity.
1. Circle your time zone on the audioconference schedule.
2. For each audioconference for which you would like to participate, check the box next to the
date(s) you prefer. Please verify correct time zone.
3. To register by phone, call 1.888.700.3720.
4.To register by mail, return this completed schedule and Registration Form
postmarked no fewer than 10 days before your selected conference to receive program
materials (workbook and instructions for participation).
5. To register by fax, fax this completed schedule and Registration Form to 1.800.496.8747
(no fewer than 10 days prior to conference).
6. For late registration (no fewer than 3 days prior to audioconference), please call
1.888.700.3720.
Fax the completed Audioconference Schedule and

---

Adv in Oncology Mailer Printout
11/17/04
1:40 PM
Page 4
Emerging Strategies for Improving Outcomes in
Multiple Myeloma
Registration Form
Physician
Nurse
Pharmacist
First Name _____________________________ MI _____ Last Name _________________________
Degree/Credentials ___________________________________________________________________
Job Title ___________________________________________________________________________
Institution _________________________________________________________________________
Home Address
Work Address
Street Address _______________________________________________________________________
City ____________________________________________ State _____ Zip ___________________
Daytime Telephone Number _____________________________________________________________
Fax Number ________________________________________________________________________
E-mail Address ______________________________________________________________________
Signature __________________________________________________________________________
If more than one participant is registering, indicate name of the call coordinator at your location ________
________________________________________________________________________
Number of Participants
MD ______
RN _______
RPh _______
Other _________________
Telephone Number ___________________________________________________________________
Fax Number ________________________________________________________________________
Do you need assistance in obtaining speaker-phone equipment for large audiences?
Yes
No
NOTE: 3 weeks advance notice needed for speaker-phone equipment.
This activity is also available on Audio CD.
Please send me the Audio CD/Workbook of this educational program. (Allow 4-6 weeks for delivery)
I
Registration Form to 1.800.496.8747

---

Adv in Oncology Mailer Printout
11/17/04
1:40 PM
Page 5
AMP
PLACE ST HERE
in
comes
Out
ingvo
rImprof
gieste lomaetray eet 11729
S
M
Strn
NY
rging
Acor
E
Park,
Eme
Multiple
561
Unit
Deer

---

Adv in Oncology Mailer Printout
11/17/04
1:40 PM
Page 6
Emerging Strategies for Improving Outcomes in
Multiple Myeloma
Accreditation
Physicians
Medical Education Resources is accredited by the Accreditation Council for Continuing Medical Education
(ACCME) to sponsor continuing medical education for physicians.
Medical Education Resources designates this educational activity for a maximum of 1 category 1
credit toward the AMA Physician's Recognition Award. Each physician should claim only those credits
that he/she actually spent in the activity.
This CME activity was planned and produced in accordance with the ACCME essentials.
Nurses
This program qualifies for 1.25 contact hours. Medical Education Resources is an approved provider of
continuing education by the Colorado Nurses Association, an accredited approver by the American Nurses
Credentialing Center's Commission on Accreditation.
Provider approved by the California Board of Registered Nursing, Provider #CEP 12299 for 1.25
contact hours.
Each participant should claim only those hours of credit that he/she actually spent in the educational
activity.
Pharmacists
Medical Education Resources (MER) is accredited by the Accreditation Council for Pharmacy
Education as a provider of continuing pharmacy education. MER designates this continuing
education activity for 1 contact hour (0.1 CEU) of the Accreditation Council for Pharmacy
Education.
Universal Program Number: 816-000-04-054-L01
Participants will be required to sign in at the start of the program. Statements of credit will be mailed within
four weeks of receipt of appropriate documentation of course completion.
Program Release Date: November 2004
Program Expiration Date: November 2005

---

Adv in Oncology Mailer Printout
11/17/04
1:40 PM
Page 7
AID
NY
MAIL
P
A,
.162
GEA
NO
-CLASS
POSTS.
FIRST
U.
MASSAPEQU
PERMIT
in
comes
Out
ingvo
rImprof
gieste lomaetray eet 11729
S
M
Strn
NY
rging
Acor
E
Park,
Eme
Multiple
561
Unit
Deer
M

---